Literature DB >> 8163537

Individual epidermal growth factor receptor autophosphorylation sites do not stringently define association motifs for several SH2-containing proteins.

C Soler1, L Beguinot, G Carpenter.   

Abstract

To determine whether individual autophosphorylation sites in the epidermal growth factor (EGF) receptor define specific interaction sites for the in vivo association of signal transduction proteins that contain src homology 2 (SH2) domains, the capacity of wild-type and mutant EGF receptors to associate with several SH2 domain-containing proteins has been assayed. Mutants included receptors with single autophosphorylation site mutations at each of five autophosphorylation sites and receptors in which multiple autophosphorylation sites were removed by point mutation or deletion of carboxyl-terminal residues. Receptor association, as measured by coimmunoprecipitation, has been determined for phospholipase C-gamma 1, the ras GTPase-activating protein, the p85 subunit of phosphatidylinositol 3-kinase, and the src homology and collagen protein. In contrast to data obtained with single autophosphorylation site mutants of other receptor tyrosine kinases, none of the EGF receptor single site mutants was dramatically impaired in its capacity to associate with any of these SH2-containing proteins. However, association was completely abrogated when all five autophosphorylation sites were mutated or removed by deletion. These results indicate that individual autophosphorylation sites in the EGF receptor are not stringently required for the recognition and association of different SH2-containing substrates. Thus, EGF receptor autophosphorylation sites seem to be flexible and/or compensatory in their capacity to mediate association with these four SH2-containing substrates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163537

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion.

Authors:  Hiroshi Nozawa; Gina Howell; Shinsuke Suzuki; Qing Zhang; Yanjun Qi; Judith Klein-Seetharaman; Alan Wells; Jennifer R Grandis; Sufi M Thomas
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

2.  Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal.

Authors:  J E Ladbury; M A Lemmon; M Zhou; J Green; M C Botfield; J Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

3.  ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.

Authors:  N J Hellyer; K Cheng; J G Koland
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

4.  Positive and negative tissue-specific signaling by a nematode epidermal growth factor receptor.

Authors:  G M Lesa; P W Sternberg
Journal:  Mol Biol Cell       Date:  1997-05       Impact factor: 4.138

5.  Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution.

Authors:  Toshimitsu Yamaoka; Mark R Frey; Rebecca S Dise; Jessica K Bernard; D Brent Polk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-05-26       Impact factor: 4.052

6.  Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking.

Authors:  P Burke; K Schooler; H S Wiley
Journal:  Mol Biol Cell       Date:  2001-06       Impact factor: 4.138

7.  The GTPase-activating protein of Ras suppresses platelet-derived growth factor beta receptor signaling by silencing phospholipase C-gamma 1.

Authors:  M Valius; J P Secrist; A Kazlauskas
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

8.  The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor.

Authors:  A G Batzer; P Blaikie; K Nelson; J Schlessinger; B Margolis
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

9.  Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study.

Authors:  G P Stathopoulos; D Trafalis; J Dimitroulis; A Athanasiou; J Koutantos; A Anagnostopoulos
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

10.  Cloning and characterization of Lnk, a signal transduction protein that links T-cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3-kinase.

Authors:  X Huang; Y Li; K Tanaka; K G Moore; J I Hayashi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.